ACLX
Arcellx, Inc.
NASDAQ · Healthcare · Biotechnology · US
$115.07
+0.02%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 22.3M | 22.3M | 107.9M | 110.3M | — |
| Cost of Revenue | 36.7M | 6.7M | 5.2M | — | 2.2M |
| Gross Profit | (14.4M) | 15.6M | 102.7M | 110.3M | (2.2M) |
| Operating Expenses | |||||
| R&D Expense | 157.6M | 157.6M | 157.1M | 133.8M | 149.6M |
| SG&A Expense | 116.1M | 117.8M | 88.4M | 66.3M | 41.7M |
| General & Admin Expense | 86.5M | 117.8M | 88.4M | 66.3M | 41.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (35.1M) | (6.7M) | (5.2M) | — | (2.2M) |
| Total Operating Expenses | 238.6M | 268.7M | 240.3M | 200.2M | 189.0M |
| Cost and Expenses | 275.4M | 275.4M | 245.5M | 200.2M | 191.3M |
| Operating Income (EBIT) | (253.1M) | (253.1M) | (137.6M) | (89.9M) | (191.3M) |
| Non-Operating | |||||
| Interest Income | 25.2M | — | 33.3M | 23.7M | 4.3M |
| Interest Expense | 24.2M | 24.2M | 1.0M | 3.8M | 1.7M |
| Net Interest Income | 1.0M | (24.2M) | 32.3M | 19.9M | 2.6M |
| Other Non-Op Income/Expense | 24.2M | 24.2M | 32.3M | 19.9M | 2.6M |
| Non-Operating Income (excl Interest) | (48.4M) | (48.4M) | (33.3M) | (23.7M) | (4.3M) |
| EBT (Pre-Tax Income) | (228.9M) | (228.9M) | (105.3M) | (70.0M) | (188.7M) |
| Income Tax Expense | 69.0K | 69.0K | 2.1M | 663.0K | — |
| Bottom Line | |||||
| Net Income | (228.9M) | (228.9M) | (107.3M) | (70.7M) | (188.7M) |
| Earnings from Cont. Ops | (228.9M) | (228.9M) | (107.3M) | (70.7M) | (188.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (228.9M) | (228.9M) | (107.3M) | (70.7M) | (188.7M) |
| Per Share | |||||
| Basic EPS | ($4.07) | ($4.07) | ($2.00) | ($1.47) | ($4.28) |
| Diluted EPS | ($4.06) | ($4.07) | ($2.00) | ($1.47) | ($4.28) |
| Revenue Per Share | $0.40 | $0.40 | $2.02 | $2.30 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 56.3M | 56.3M | 53.6M | 48.1M | 44.1M |
| Diluted Shares Outstanding | 56.3M | 56.3M | 53.6M | 48.1M | 44.1M |
| Profitability Metrics | |||||
| EBITDA | (198.0M) | (198.0M) | (99.1M) | (64.1M) | (184.7M) |
| D&A | 6.7M | 6.7M | 5.2M | 2.0M | 2.2M |
| EBIT | (204.6M) | (204.6M) | (104.2M) | (66.2M) | (187.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025